ZBIO Zenas BioPharma, Inc.
USHealthcareAs of 2026-07-08 16:00
Why ZBIO matters now
Zenas BioPharma, Inc. (ZBIO) is a US stock in Healthcare. The latest InvestLog snapshot shows $28.77 with +3.92% on the session and $1.28B in market capitalization; recent performance reads 1-month +10.87% and YTD -45.52%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-81.0M, and EPS of $-1.46. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -23.8%.
The latest indexable market news headline is "Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction." from The Motley Fool.
Additional event context on this page matters because analyst consensus is Buy with a median target of $35.00; recent insider activity includes Fox Jennifer A. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.28
P/S
0.00
EV/EBITDA
-1.80
DCF Value
$-0.30
FCF Yield
-23.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-167.7%
ROA
-56.9%
ROIC
-61.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-81.0M | $-1.46 |
| Q4 2025 | $0.00 | $-240.4M | $-5.17 |
| FY 2025 | $10.0M | $-377.7M | $-8.44 |
| Q3 2025 | $0.00 | $-51.5M | $-1.22 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$35.00
Target (Median)
$35.00
Target Range
$22.00 - $48.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.69
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.